|Last Update: 05/17/13 - 4:00 PM EDT|
|YTD Performance: -5.61%|
|Previous Close: $48.29|
|52 Week Range: $39.36 - $59.24|
|Oustanding Shares: 74,976,902|
|Market Cap: 3,620,634,598|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||11||12||10||11|
|Growth Rate (Year over Year)||-210.30%||-326.39%||-85.71%||145.98%|
MDVN was initiated with a Buy rating, Needham said. Xtandi is rapidly gaiing market share for the treatment of prostate cancer.
MDVN was initiated with a Neutral rating, UBS said. $59 price target. Xtandi should drive conversion to profitability, but peak expectations high.
Shares of MDVN now seen reaching $62, Jefferies said. Estimates also raised on Xtandi beat. Buy rating.
Adam Feuerstein, Sr. Columnist for TheStreet, says biotech earnings are the next big things to watch in biotech.
Shares of MDVN now seen reaching $70, Citigroup said. Estimates also increased to reflect higher Xtandi US price. Buy rating.
Motivated CEOs, innovative products and smart deals count more than macro events.
Shares of MDVN now seen reaching $122, Jefferies said. Estimates also raised on Xtandi approval. Buy rating.
Shares of MDVN now seen reaching $149, according to Credit Suisse. Estimates also increased, given the earlier-than-expected approval of Xtandi. Outperform rating.
Shares of MDVN now seen reaching $120, according to Credit Suisse. Estimates also reduced, given rising operating costs. Outperform rating.
These mid-caps are volatile, but a merger or major announcement could send them soaring.